XML 27 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 7 - Employee and Director Benefits
9 Months Ended
Sep. 30, 2022
Notes to Financial Statements  
Share-Based Payment Arrangement [Text Block]

NOTE 7 - EMPLOYEE AND DIRECTOR BENEFITS

 

Stock Options

 

The Company has a stock incentive plan as described below. The compensation cost that has been charged to earnings for the plan was approximately $804,000 and $2.4 million for the three and nine months ended September 30, 2022, respectively, and $461,000 and $1.3 million for the three and nine months ended September 30, 2021, respectively.

 

The Company’s 2009 Amended and Restated Stock Incentive Plan authorizes the grant of up to 5,550,000 shares and allows for the issuance of Stock Appreciation Rights, Restricted Stock, Stock Options, Non-stock Share Equivalents, Performance Shares or Performance Units. The plan allows for the grant of incentive stock options and non-qualified stock options, and option awards are granted with an exercise price equal to the fair market value of the Company’s common stock at the date of grant. The maximum term of the options granted under the plan is ten years.

 

The Company estimates the fair value of each stock option award using a Black-Scholes-Merton valuation model which incorporates the assumptions noted in the following table. Expected volatilities are based on an index of southeastern United States publicly traded banks. The expected term for options granted is based on the simplified method and represents the period of time that options granted are expected to be outstanding. The risk-free rate for periods within the contractual life of the option is based on the U. S. Treasury yield curve in effect at the time of grant.

 

  

2021

 

Expected volatility

  40.00

%

Expected dividends

  1.78

%

Expected term (in years)

  7.5 

Risk-free rate

  2.43

%

 

There were no grants of stock options during the nine months ended September 30, 2022. The weighted average grant-date fair value of options granted during the nine months ended September 30, 2021 was $12.73.

 

The following table summarizes stock option activity during the nine months ended September 30, 2022 and September 30, 2021:

 

          

Weighted

     
      

Weighted

  

Average

     
      

Average

  

Remaining

  

Aggregate

 
      

Exercise

  

Contractual

  

Intrinsic

 
  

Shares

  

Price

  

Term (years)

  

Value

 
              

(In Thousands)

 

Nine Months Ended September 30, 2022:

                

Outstanding at January 1, 2022

  353,250  $19.28   3.8  $23,525 

Exercised

  (65,500)  16.42   2.3   4,164 

Forfeited

  (1,500)  35.21   5.8   67 

Outstanding at September 30, 2022

  286,250   19.51   3.4  $18,431 
                 

Exercisable at September 30, 2022

  225,500  $14.89   2.3  $14,990 
                 

Nine Months Ended September 30, 2021:

                

Outstanding at January 1, 2021

  640,950  $18.14   4.6  $16,981 

Granted

  500   32.60   7.7   23 

Exercised

  (257,200)  12.46   3.2   16,805 

Forfeited

  (9,000)  16.57   2.1   256 

Outstanding at September 30, 2021

  375,250  $19.56   4.1  $22,438 
                 

Exercisable at September 30, 2021

  281,000  $12.79   3.0  $18,565 

 

As of September 30, 2022, there was $246,000 of total unrecognized compensation cost related to non-vested stock options. The cost is expected to be recognized on the straight-line method over the next 1.4 years.

 

Restricted Stock and Performance Shares

 

The Company periodically grants restricted stock awards that vest upon time-based service conditions. Dividend payments are made during the vesting period. The value of restricted stock is determined to be the current value of the Company’s stock, and this total value will be recognized as compensation expense over the vesting period. As of September 30, 2022, there was $5.0 million of total unrecognized compensation cost related to non-vested time-based restricted stock. The cost is expected to be recognized evenly over the remaining 2.5 years of the restricted stock’s vesting period.

 

The Company periodically grants performance shares that give plan participants the opportunity to earn between 0% and 150% of the number of performance shares granted based on achieving certain performance metrics. The number of performance shares earned is determined by reference to the Company’s total shareholder return relative to a peer group of other publicly traded banks and bank holding companies during the performance period. The performance period is generally three years starting on the grant date. The fair value of the performance shares is determined using a Monte Carlo simulation model on the grant date. As of September 30, 2022, there was $907,000 of total unrecognized compensation cost related to non-vested performance shares. As of September 30, 2022, non-vested performance shares had a weighted average remaining time to vest of 2.0 years.

 

  

Restricted Stock

  

Performance Shares

 
  

Shares

  

Weighted
Average Grant
Date Fair
Value

  

Shares

  

Weighted
Average Grant
Date Fair
Value

 

Nine Months Ended September 30, 2022:

                

Non-vested at January 1, 2022

  127,602  $42.27   12,437  $37.05 

Granted

  52,819   83.33   11,415   72.81 

Vested

  (26,563)  43.51   -   - 

Forfeited

  (8,206)  61.70   -   - 

Non-vested at September 30, 2022

  145,652  $55.84   23,852  $54.16 
                 

Nine Months Ended September 30, 2021:

                

Non-vested at January 1, 2021

  84,307  $34.92   -  $- 

Granted

  69,295   48.92   12,437   37.05 

Vested

  (13,024)  28.44   -   - 

Forfeited

  (11,725)  39.59   -   - 

Non-vested at September 30, 2021

  128,853  $42.68   12,437  $37.05